POINT Biopharma Global Inc

NASDAQ:PNT  
7.98
-0.03 (-0.38%)
Products, Regulatory

Point Biopharma Releases New Data, Exercises Option For Best-In-Class FAP Inhibitor

Published: 09/28/2021 12:38 GMT
POINT Biopharma Global Inc (PNT) - Point Biopharma Releases New Data and Exercises Option for Best-in-class Fap Inhibitor.
Point Biopharma Global Inc - Initiation of a Phase 1 Therapeutic Clinical Trial Planned for 1h2022.
Point Biopharma - New Data Demonstrates Characteristics Including Rapid and Persistent Tumor Targeting With Very Low Retention in Normal Tissues.
Point Biopharma Global Inc - Exercised Its Option on Technology and Amended Exclusive Global Licensing Agreement With Bach Biosciences.